Colorectal Cancer Screening and Diagnostics Market - A Global and Regional Analysis: Focus on Type, End User, Region, and Competitive Landscape, Pricing Analysis, Testing Volume - Analysis and Forecast, 2023-2033

Report Highlights

The Global Colorectal Cancer Screening and Diagnostics Market Expected to Reach $48.71 Billion by 2033

Global Colorectal Cancer Screening and Diagnostics Market Overview

The global colorectal cancer screening and diagnostics market is projected to experience substantial growth over the forecast period 2023-2033. Moreover, the market value for 2022 was $37,145.8 million, which is expected to reach $48,710.9 million by 2033, growing at a CAGR of 2.37% during the forecast period. This growth can be attributed to the rising incidence of colorectal cancer and increasing financial burden on healthcare, growing demand for colorectal cancer testing, advances in genomics and molecular diagnostics, and promoting early cancer detection to enable reduced treatment costs. The market includes various types of tests, such as stool DNA tests, fecal immunochemical tests, fecal occult blood tests, biomarker tests, colonoscopies, and sigmoidoscopies.

Market Lifecycle Stage

The colorectal cancer screening and diagnostics market is currently at a growing stage with a robust growth trajectory, propelled by the rising demand for at-home colorectal cancer screening and diagnostics. The market is characterized by a mix of well-established companies and innovative startups, all competing to offer advanced solutions that cater to the evolving demands of research and diagnostics.

Industry Impact

The global colorectal cancer screening and diagnostics market’s impact is profound and multifaceted, influencing healthcare practices, patient outcomes, and economic dynamics within the healthcare sector. The market's growth is driving a significant shift toward early detection and prevention, leading to improved survival rates and quality of life for patients. This shift is also catalyzing a transition in healthcare focus from treatment to prevention, encouraging the development of public health policies and insurance coverage that support regular screening.

Economically, the expansion of the colorectal cancer screening and diagnostics market has been contributing to the healthcare industry's growth, owing to increased investments in research and development of more accurate and less invasive screening technologies. These innovations not only enhance patient compliance and comfort but also have the potential to reduce long-term healthcare costs by preventing advanced disease stages that require more intensive and expensive treatments.

The global colorectal cancer screening and diagnostics market continues to drive transformative advancements across industries, with far-reaching implications for human health and environmental sustainability.

Market Segmentation

Segmentation 1: by Type

• Stool DNA Test
• Fecal Immunochemical Test (FIT)
• Fecal Occult Blood Test (FOBT)
• Colonoscopies and Sigmoidoscopies
• Biomarkers Test

Colonoscopies and Sigmoidoscopies to Dominate the Global Colorectal Cancer Screening and Diagnostics Market (by Type)

Based on type, the colonoscopies and sigmoidoscopies segment dominated the global colorectal cancer screening and diagnostics market in FY2022. This category includes colonoscopes and sigmoidoscopes, which are considered a gold standard for diagnosis and screening for colorectal cancer. Colonoscopy allows for a detailed examination of the entire colon and rectum, enabling the detection of not only cancers but also precancerous polyps, which can be removed during the same procedure to prevent cancer development. Sigmoidoscopy, while more limited in scope, examining only the lower part of the colon, still plays a crucial role in screening efforts, especially in cases where a full colonoscopy might not be necessary or feasible.

Segmentation 2: by End User

• Hospitals and Clinics
• Ambulatory Centers
• Clinical Laboratories
• Others

Hospitals and Clinics Segment to Hold its Dominance in the Global Colorectal Cancer Screening and Diagnostics Market (by End User)

Based on end user, the hospitals and clinics accounted for the largest share of the global colorectal cancer screening and diagnostics market in FY2022 due to the comprehensive healthcare services offered by them, including advanced diagnostic facilities and the availability of specialized care, which enable early detection and management of colorectal cancer.

Segmentation 3: by Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

The North America region is a leader in the global colorectal cancer screening and diagnostics market, a position it is expected to maintain over the coming years. This dominance can be attributed to several key factors, including high awareness levels regarding colorectal cancer, and the implementation of comprehensive screening programs across the U.S. and Canada.

Recent Developments in the Global Colorectal Cancer Screening and Diagnostics Market

• In February 2024, Exact Sciences Corporation announced gearing up for the launch of a new slate of assays over the next few years, including a new iteration of its well-established stool-based colorectal cancer screening test, Cologuard, a complementary blood-based assay and a test for minimal residual disease detection.
• In February 2024, Freenome Holdings, Inc. announced that it raised $254 million in a new funding round led by Swiss drugmaker Roche to develop tests that could potentially detect multiple early-stage cancers and is currently developing screening tests focused on colorectal and lung cancers.
• In May 2023, Guardant Health collaborated with the Ohio State University Comprehensive Cancer Center to study colorectal cancer screening adherence.
• In May 2023, Guardant Health submitted a premarket approval application to the U.S. Food and Drug Administration for a Shield blood test.
• In April 2023, Mainz Biomed revealed a collaboration with the Instituto de Microecologia aimed at broadening ColoAlert's commercial reach in both Spain and Portugal.
• In May 2023, Olympus Corporation introduced the CF-HQ1100DL/I colon videoscope, a device specifically created for the inspection of the lower digestive system, covering areas such as the anus, rectum, sigmoid colon, colon, and ileocecal valve. This launch would serve to enhance Olympus's range of products within the colorectal cancer screening and diagnostics sector.

Demand - Drivers, Restraints, and Opportunities

Market Demand Drivers:

Rising Incidence of Colorectal Cancer and Increasing Financial Burden on Healthcare: The increasing healthcare expenditure related to colorectal cancer reflects the growing costs associated with its prevention, diagnosis, treatment, and management. As the incidence of colorectal cancer rises, the economic burden of the disease is also increasing. These costs include direct medical costs such as hospitalization, surgery, chemotherapy, and radiation therapy.

Market Restraints:

Limited Sensitivity of FIT/FOBT Testing Kits: While non-invasive testing techniques for colorectal cancer, such as fecal immunochemical tests and stool DNA tests, have shown significant potential in cancer detection, they do have some limitations. One of the major limitations is their limited sensitivity, meaning they may not detect all cases of colorectal cancer, particularly in the early stages. This can result in false negatives and delayed diagnosis, which can impact patient outcomes.

Market Opportunities:

Expansion of Screening Programs: Population-wide screening programs are proving to be a lucrative opportunity for the colorectal cancer screening and diagnostic market by leading to an increased number of individuals being screened for colorectal cancer, leading to earlier detection and treatment of the disease. By improving access to screening, these programs can also reduce healthcare costs and improve patient outcomes associated with more advanced stages of the disease, thereby resulting in a strong interest in these testing methodologies by various government and NGO screening programs.

How can this report add value to an organization?

Workflow/Innovation Strategy: The global colorectal cancer screening and diagnostics market (by product) has been segmented into detailed segments, including different types of tests, such as fecal immunochemical tests, fecal occult tests, stool DNA tests, biomarker tests, and colonoscopies and sigmoidoscopies.

Growth/Marketing Strategy: A strategic growth and marketing approach for the colorectal cancer screening and diagnostics market would involve positioning the company as a leader in innovative solutions that address the evolving needs of hospitals, clinicians, laboratories, and pharmaceutical partners. This would entail leveraging technological advancements to develop products with enhanced sensitivity and specificity while also investing in comprehensive, collaborative partnerships to foster customer loyalty and drive market penetration.

Competitive Strategy: Key players in the global colorectal cancer screening and diagnostics market have been focusing on innovation, differentiation, and strategic collaborations to gain a competitive edge. By investing in research and development, companies can develop novel screening and diagnostics methods, improve test sensitivity, and expand application areas.